fda warning letters compounded semaglutide tirzepatide 2025 glp-1 compounding october Pharmacovigilance Assessment of GLP-1 Receptor Agonists: Insights From the FDA Adverse Event Reporting System New project announcement: HHS‑OIG is

Purpose-built for physicians Q&A: Liraglutide outperforms colesevelam in reducing stool frequency in bile acid diarrhea Liraglutide reduced stool frequency in a small subset of patients with bile acid diarrhea and warrants consideration as a potential new treatment modality, according to research in The Lancet Gastroenterology and Hepatology

Longer and larger studies should be conducted to confirm these preliminary findings

Chen N, Reith ME

It can merge with the cells in your small intestine and deliver the glutathione directly into the bloodstream

Nausea and vomiting are common side effects of tirzepatide, which may affect how you absorb oral contraceptives, antibiotics, or other critical medications